Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report. Issue 2 (7th March 2015)

• Record Type: Journal Article
• Authors: Detroyer, D.; Deraedt, K.; Schöffski, P.; Hauben, E.; Lagrou, K.; Naesens, M.; Delforge, M.‐L.; Kuypers, D.
• Is Part Of: Transplant infectious disease. Volume 17:Issue 2(2015)
• Page Start: 303
• Page End: 307
• Publication Date: 2015-03-07
• Subjects: mTOR inhibitor -- Kaposi's sarcoma -- immunosuppression -- Kaposi's sarcoma herpesvirus -- renal transplantation -- Pyrenochaeta romeroi; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12357
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: We present a case report of a patient with diffuse skin and systemic Kaposi's sarcoma (KS), 1 year after renal transplantation. A concomitant Pyrenochaeta romeroi granuloma of the right hallux was diagnosed and illustrated an important immunodysfunction in our patient. Four months after reduction in immunosuppression and switch to everolimus, a total regression of the KS was observed. Reduction in the immunosuppression and treatment with terbinafine cleared the P. romeroi infection, while lowering immunosuppression and changing the type of immunosuppressive therapy were important steps in the successful management of the KS. In recent years, evidence of the antitumor effects of everolimus is increasing: total regression of KS in combination with renal function preservation in renal graft recipients is possible with mammalian target of rapamycin (mTOR) inhibitor‐based regimens. In addition, with increasing numbers of human immunodeficiency virus‐positive transplant recipients, mTOR inhibitors may play a more crucial role in the management of KS.